Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride
Radionuclide therapy with 223Ra-dichloride is used to treat bone metastases and to improve the quality of life of patients with metastatic castration-resistant prostate cancer. At the present time there is no reliable data on the biodistribution of the 223Ra-dichloride in the patient body. The aim o...
| Главные авторы: | , , , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev
2020-12-01
|
| Серии: | Радиационная гигиена |
| Предметы: | |
| Online-ссылка: | https://www.radhyg.ru/jour/article/view/747 |
| _version_ | 1826546620666216448 |
|---|---|
| author | L. A. Chipiga A. E. Petrova A. V. Vodovatov A. A. Stanzhevsky A. A. Lumpov D. D. Lavreshov L. E. Naurzbaeva S. M. Kushnarenko A. A. Mosunov |
| author_facet | L. A. Chipiga A. E. Petrova A. V. Vodovatov A. A. Stanzhevsky A. A. Lumpov D. D. Lavreshov L. E. Naurzbaeva S. M. Kushnarenko A. A. Mosunov |
| author_sort | L. A. Chipiga |
| collection | DOAJ |
| description | Radionuclide therapy with 223Ra-dichloride is used to treat bone metastases and to improve the quality of life of patients with metastatic castration-resistant prostate cancer. At the present time there is no reliable data on the biodistribution of the 223Ra-dichloride in the patient body. The aim of this study was to assess absorbed, equivalent doses in radiosensitive organs and tissues and effective dose from internal exposure for patients with metastatic castration-resistant prostate cancer treated with 223Ra-dichloride. Internal doses from 223Ra-dichloride were calculated for a chamber model specific for patients with metastatic castration-resistant prostate cancer. This model consists of 8 chambers (blood plasma, two chambers describing bone tissue, small intestine, upper large intestine, lower large intestine, feces and the rest of the body). Time-integrated activities were calculated using the SAAM II v2.3 software. The IDAC-Dose 2.1 software was used to calculate the absorbed doses. The highest absorbed doses in organs and equivalent doses were determined for the bone surface and red bone marrow. The absorbed dose from a-radiation in the bone surface for a set of six therapeutic procedures with 223Ra-dichloride was estimated as 1 Gy; in the red bone marrow — 0.14 Gy. However, the approach used does not specifically consider accumulation of the radiopharmaceutical in metastases, which can lead to a significant overestimation of the absorbed dose in the healthy part of the bone surface and red bone marrow. |
| first_indexed | 2024-04-10T01:21:57Z |
| format | Article |
| id | doaj.art-9277b86f6cef4250bd8b8593ae0377eb |
| institution | Directory Open Access Journal |
| issn | 1998-426X |
| language | English |
| last_indexed | 2025-03-14T05:36:39Z |
| publishDate | 2020-12-01 |
| publisher | Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev |
| record_format | Article |
| series | Радиационная гигиена |
| spelling | doaj.art-9277b86f6cef4250bd8b8593ae0377eb2025-03-05T14:03:19ZengSaint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. RamzaevРадиационная гигиена1998-426X2020-12-0113461610.21514/1998-426X-2020-13-4-6-16668Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichlorideL. A. Chipiga0A. E. Petrova1A. V. Vodovatov2A. A. Stanzhevsky3A. A. Lumpov4D. D. Lavreshov5L. E. Naurzbaeva6S. M. Kushnarenko7A. A. Mosunov8Saint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being; A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies; Almazov National Medical Research CentrePeter the Great Saint-Petersburg Polytechnic UniversitySaint-Petersburg Research Institute of Radiation Hygiene after Professor P.V. Ramzaev, Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being; Saint-Petersburg State Pediatric Medical UniversityA.M. Granov Russian Scientific Center of Radiology and Surgical TechnologiesKhlopin Radium InstitutePeter the Great Saint-Petersburg Polytechnic UniversityPeter the Great Saint-Petersburg Polytechnic UniversityPeter the Great Saint-Petersburg Polytechnic UniversityPeter the Great Saint-Petersburg Polytechnic UniversityRadionuclide therapy with 223Ra-dichloride is used to treat bone metastases and to improve the quality of life of patients with metastatic castration-resistant prostate cancer. At the present time there is no reliable data on the biodistribution of the 223Ra-dichloride in the patient body. The aim of this study was to assess absorbed, equivalent doses in radiosensitive organs and tissues and effective dose from internal exposure for patients with metastatic castration-resistant prostate cancer treated with 223Ra-dichloride. Internal doses from 223Ra-dichloride were calculated for a chamber model specific for patients with metastatic castration-resistant prostate cancer. This model consists of 8 chambers (blood plasma, two chambers describing bone tissue, small intestine, upper large intestine, lower large intestine, feces and the rest of the body). Time-integrated activities were calculated using the SAAM II v2.3 software. The IDAC-Dose 2.1 software was used to calculate the absorbed doses. The highest absorbed doses in organs and equivalent doses were determined for the bone surface and red bone marrow. The absorbed dose from a-radiation in the bone surface for a set of six therapeutic procedures with 223Ra-dichloride was estimated as 1 Gy; in the red bone marrow — 0.14 Gy. However, the approach used does not specifically consider accumulation of the radiopharmaceutical in metastases, which can lead to a significant overestimation of the absorbed dose in the healthy part of the bone surface and red bone marrow.https://www.radhyg.ru/jour/article/view/747radionuclide therapy223ra-dichlorideprostate cancerradiopharmaceuticalsinternal doseabsorbed doses in organsequivalent doseeffective dose |
| spellingShingle | L. A. Chipiga A. E. Petrova A. V. Vodovatov A. A. Stanzhevsky A. A. Lumpov D. D. Lavreshov L. E. Naurzbaeva S. M. Kushnarenko A. A. Mosunov Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride Радиационная гигиена radionuclide therapy 223ra-dichloride prostate cancer radiopharmaceuticals internal dose absorbed doses in organs equivalent dose effective dose |
| title | Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride |
| title_full | Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride |
| title_fullStr | Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride |
| title_full_unstemmed | Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride |
| title_short | Patient organ and effective dose estimation in radionuclide therapy with <sup>223</sup>Ra -dichloride |
| title_sort | patient organ and effective dose estimation in radionuclide therapy with sup 223 sup ra dichloride |
| topic | radionuclide therapy 223ra-dichloride prostate cancer radiopharmaceuticals internal dose absorbed doses in organs equivalent dose effective dose |
| url | https://www.radhyg.ru/jour/article/view/747 |
| work_keys_str_mv | AT lachipiga patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT aepetrova patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT avvodovatov patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT aastanzhevsky patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT aalumpov patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT ddlavreshov patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT lenaurzbaeva patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT smkushnarenko patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride AT aamosunov patientorganandeffectivedoseestimationinradionuclidetherapywithsup223supradichloride |